Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies

K. T. Robbins, Anna Maria Storniolo, C. Kerber, S. Seagren, A. Berson, S. B. Howell

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Advances in vascular radiology techniques for superselective arterial infusions and methods to overcome systemic toxicity from high-dose cisplatin chemotherapy encouraged us to reevaluate the effects of rapid regional cisplatin infusion for patients with head and neck malignancies. Twenty patients (17 carcinomas, three sarcomas) received high-dose cisplatin (100- 200 mg/m2) by this method. Fifteen of the 17 patients with upper aerodigestive tract carcinoma are part of an ongoing phase I dose escalation of cisplatin with sodium thiosulfate neutralization. Three additional patients with sarcomas were treated with intra-arterial (IA) cisplatin and systemic Adriamycin. Fifty-three IA infusions were performed without any complications. Only minimal toxicity related to the chemotherapy was observed. The overall response rate for previously untreated patients was nine of 10 (90%) [complete response (CR) 67%; partial response (PR) 33%]. The response rate for patients with recurrent disease was five of eight (63%) (CR 20%, PR 80%). The average length of follow-up is 9.5 months and the actuarial survival rate is 56%. Superselective rapid infusion of high-dose cisplatin for patients with advanced head and neck malignancies is feasible, relatively nontoxic, and may have important applications in multimodality therapy, particularly for patients with bulky primary disease.

Original languageEnglish (US)
Pages (from-to)364-371
Number of pages8
JournalHead and Neck
Volume14
Issue number5
StatePublished - 1992
Externally publishedYes

Fingerprint

Cisplatin
Neck
Head
Neoplasms
Sarcoma
Carcinoma
Drug Therapy
Intra Arterial Infusions
Radiology
Doxorubicin
Blood Vessels
Survival Rate

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Robbins, K. T., Storniolo, A. M., Kerber, C., Seagren, S., Berson, A., & Howell, S. B. (1992). Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head and Neck, 14(5), 364-371.

Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. / Robbins, K. T.; Storniolo, Anna Maria; Kerber, C.; Seagren, S.; Berson, A.; Howell, S. B.

In: Head and Neck, Vol. 14, No. 5, 1992, p. 364-371.

Research output: Contribution to journalArticle

Robbins, KT, Storniolo, AM, Kerber, C, Seagren, S, Berson, A & Howell, SB 1992, 'Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies', Head and Neck, vol. 14, no. 5, pp. 364-371.
Robbins, K. T. ; Storniolo, Anna Maria ; Kerber, C. ; Seagren, S. ; Berson, A. ; Howell, S. B. / Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. In: Head and Neck. 1992 ; Vol. 14, No. 5. pp. 364-371.
@article{df3c1179126f40ba9b9132e4ea73ed52,
title = "Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies",
abstract = "Advances in vascular radiology techniques for superselective arterial infusions and methods to overcome systemic toxicity from high-dose cisplatin chemotherapy encouraged us to reevaluate the effects of rapid regional cisplatin infusion for patients with head and neck malignancies. Twenty patients (17 carcinomas, three sarcomas) received high-dose cisplatin (100- 200 mg/m2) by this method. Fifteen of the 17 patients with upper aerodigestive tract carcinoma are part of an ongoing phase I dose escalation of cisplatin with sodium thiosulfate neutralization. Three additional patients with sarcomas were treated with intra-arterial (IA) cisplatin and systemic Adriamycin. Fifty-three IA infusions were performed without any complications. Only minimal toxicity related to the chemotherapy was observed. The overall response rate for previously untreated patients was nine of 10 (90{\%}) [complete response (CR) 67{\%}; partial response (PR) 33{\%}]. The response rate for patients with recurrent disease was five of eight (63{\%}) (CR 20{\%}, PR 80{\%}). The average length of follow-up is 9.5 months and the actuarial survival rate is 56{\%}. Superselective rapid infusion of high-dose cisplatin for patients with advanced head and neck malignancies is feasible, relatively nontoxic, and may have important applications in multimodality therapy, particularly for patients with bulky primary disease.",
author = "Robbins, {K. T.} and Storniolo, {Anna Maria} and C. Kerber and S. Seagren and A. Berson and Howell, {S. B.}",
year = "1992",
language = "English (US)",
volume = "14",
pages = "364--371",
journal = "Head and Neck Surgery",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies

AU - Robbins, K. T.

AU - Storniolo, Anna Maria

AU - Kerber, C.

AU - Seagren, S.

AU - Berson, A.

AU - Howell, S. B.

PY - 1992

Y1 - 1992

N2 - Advances in vascular radiology techniques for superselective arterial infusions and methods to overcome systemic toxicity from high-dose cisplatin chemotherapy encouraged us to reevaluate the effects of rapid regional cisplatin infusion for patients with head and neck malignancies. Twenty patients (17 carcinomas, three sarcomas) received high-dose cisplatin (100- 200 mg/m2) by this method. Fifteen of the 17 patients with upper aerodigestive tract carcinoma are part of an ongoing phase I dose escalation of cisplatin with sodium thiosulfate neutralization. Three additional patients with sarcomas were treated with intra-arterial (IA) cisplatin and systemic Adriamycin. Fifty-three IA infusions were performed without any complications. Only minimal toxicity related to the chemotherapy was observed. The overall response rate for previously untreated patients was nine of 10 (90%) [complete response (CR) 67%; partial response (PR) 33%]. The response rate for patients with recurrent disease was five of eight (63%) (CR 20%, PR 80%). The average length of follow-up is 9.5 months and the actuarial survival rate is 56%. Superselective rapid infusion of high-dose cisplatin for patients with advanced head and neck malignancies is feasible, relatively nontoxic, and may have important applications in multimodality therapy, particularly for patients with bulky primary disease.

AB - Advances in vascular radiology techniques for superselective arterial infusions and methods to overcome systemic toxicity from high-dose cisplatin chemotherapy encouraged us to reevaluate the effects of rapid regional cisplatin infusion for patients with head and neck malignancies. Twenty patients (17 carcinomas, three sarcomas) received high-dose cisplatin (100- 200 mg/m2) by this method. Fifteen of the 17 patients with upper aerodigestive tract carcinoma are part of an ongoing phase I dose escalation of cisplatin with sodium thiosulfate neutralization. Three additional patients with sarcomas were treated with intra-arterial (IA) cisplatin and systemic Adriamycin. Fifty-three IA infusions were performed without any complications. Only minimal toxicity related to the chemotherapy was observed. The overall response rate for previously untreated patients was nine of 10 (90%) [complete response (CR) 67%; partial response (PR) 33%]. The response rate for patients with recurrent disease was five of eight (63%) (CR 20%, PR 80%). The average length of follow-up is 9.5 months and the actuarial survival rate is 56%. Superselective rapid infusion of high-dose cisplatin for patients with advanced head and neck malignancies is feasible, relatively nontoxic, and may have important applications in multimodality therapy, particularly for patients with bulky primary disease.

UR - http://www.scopus.com/inward/record.url?scp=0026756177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026756177&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 364

EP - 371

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 1043-3074

IS - 5

ER -